Is Mounjaro approved for weight loss in the UK?

Mounjaro (tirzepatide) is approved by the UK medicines regulator (MHRA) for weight management and weight loss in adults, including those with obesity (BMI ≥30) or those who are overweight (BMI 27–30) with weight-related health problems, alongside a reduced-calorie diet and increased physical activity. NICE has also recommended tirzepatide for weight management on the NHS, with England and Wales implementing a phased rollout prioritising people at highest clinical risk from mid-2025. In practical terms, this means it is authorised nationally for weight loss, and NHS access is being introduced gradually under strict eligibility criteria set by national guidance. These decisions follow the MHRA’s authorisation on 8 November 2023, which formally licensed Mounjaro for weight loss and weight management in the UK.

• MHRA authorisation date: 8 November 2023.
• Licensed population: Adults with BMI ≥30, or BMI 27–30 with weight-related conditions, used with diet and activity changes.
• NHS access: NICE-supported rollout prioritising those at highest clinical need from 2025.
• Service delivery: Phased access via specialist and GP services under strict criteria.
• Scope: UK-wide approval by MHRA; NHS availability is being implemented in stages.

Sources

• MHRA — Authorises Mounjaro for weight management and weight loss
• NHS England — Weight management injections overview
• Diabetes UK — Mounjaro (tirzepatide) information
• UK Government — GLP-1 medicines for weight loss and diabetes: what you need to know
• BBC News — NHS plans and access for anti-obesity medicines